Literature DB >> 30514595

Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin.

Brandon Kulengowski1, Justin A Clark1, David S Burgess2.   

Abstract

Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amikacin; Carbapenem-resistant Enterobacteriaceae; Meropenem; Polymyxin B; Time kill

Mesh：

Substances：

Year:  2018        PMID： 30514595     DOI： 10.1016/j.diagmicrobio.2018.10.020

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  1 in total

1.  Impact of an Intervention to Control Imipenem-Resistant Acinetobacter baumannii and Its Resistance Mechanisms: An 8-Year Survey.

Authors:  Lida Chen; Pinghai Tan; Jianming Zeng; Xuegao Yu; Yimei Cai; Kang Liao; Penghao Guo; Yili Chen; Zongwen Wu; Pinghua Qu; Renxin Cai; Cha Chen; Bin Huang
Journal:  Front Microbiol       Date:  2021-02-16       Impact factor: 5.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.